Cytokinetics, Incorporated
CYTK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $67 | $2 | $17 |
| % Growth | -97.1% | 4,128.6% | -90.7% | – |
| Cost of Goods Sold | $3 | $2 | $100 | $94 |
| Gross Profit | -$1 | $64 | -$98 | -$77 |
| % Margin | -38.4% | 96.6% | -6,223.1% | -453.1% |
| R&D Expenses | $99 | $113 | $100 | $94 |
| G&A Expenses | $69 | $66 | $57 | $62 |
| SG&A Expenses | $69 | $66 | $57 | $62 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3 | -$2 | -$100 | -$94 |
| Operating Expenses | $166 | $176 | $57 | $62 |
| Operating Income | -$167 | -$112 | -$156 | -$139 |
| % Margin | -8,613.4% | -167% | -9,856.3% | -821.4% |
| Other Income/Exp. Net | -$139 | -$23 | -$6 | -$11 |
| Pre-Tax Income | -$306 | -$134 | -$161 | -$150 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$306 | -$134 | -$161 | -$150 |
| % Margin | -15,815% | -201.2% | -10,220.1% | -886.3% |
| EPS | -2.55 | -1.12 | -1.36 | -1.27 |
| % Growth | -127.7% | 17.6% | -7.1% | – |
| EPS Diluted | -2.55 | -1.12 | -1.36 | -1.27 |
| Weighted Avg Shares Out | 120 | 119 | 118 | 118 |
| Weighted Avg Shares Out Dil | 120 | 119 | 118 | 118 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $13 | $14 | $15 |
| Interest Expense | $26 | $24 | $23 | $23 |
| Depreciation & Amortization | $3 | $2 | $2 | $2 |
| EBITDA | -$277 | -$108 | -$136 | -$125 |
| % Margin | -14,317% | -161.5% | -8,621.3% | -738.7% |